임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

38건 표시

1상모집 중단 (진행 중)· Type 2 Diabetes Mellitus (T2DM)
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers
리드: 셀트리온
상세 →NCT07533539
1상완료· Healthy Male Subjects
A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects
리드: 셀트리온
상세 →NCT07367958
1상모집 중단 (진행 중)· Healthy Participants
Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
리드: 셀트리온
상세 →NCT07200986
1상완료· Healthy
A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers
리드: 셀트리온
상세 →NCT07128654
1상완료· Type 2 Diabetes Mellitus (T2DM)
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers
리드: 셀트리온
상세 →NCT07158346
1상완료· Healthy Male Subjects
A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects
리드: 셀트리온
상세 →NCT06951828
1상완료· Healthy
To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)
리드: 셀트리온
상세 →NCT06687928
1상완료· Healthy Male Subjects
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects
리드: 셀트리온
상세 →NCT07054970
1상완료· Essential Hypertension
A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers
리드: 셀트리온
상세 →NCT05993806
1상상태 미확인· Healthy Subjects
Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects
리드: 셀트리온
상세 →NCT05617183
1상완료· Healthy
A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers
리드: 셀트리온
상세 →NCT05581693
1상완료· Healthy
A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy Volunteers
리드: 셀트리온
상세 →NCT05568121
1상완료· Healthy
A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers
리드: 셀트리온
상세 →NCT05364164
1상완료· Healthy
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
리드: 셀트리온
상세 →NCT05363592
1상완료· Healthy
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
리드: 셀트리온
상세 →NCT05363384
1상상태 미확인· Healthy Subjects
A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
리드: 셀트리온
상세 →NCT05188378
1상완료· SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
리드: 셀트리온
상세 →NCT05017168
1상완료· Healthy Subject
Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
리드: 셀트리온
상세 →NCT06037395
1상완료· Health, Subjective
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers
리드: 셀트리온
상세 →NCT05009368
1상완료· Health, Subjective
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers
리드: 셀트리온
상세 →NCT05002244
1상조기 종료· Cardiomyopathy, Hypertrophic Obstructive
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
리드: 셀트리온
상세 →NCT04418297
1상완료· Healthy Male Subjects
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
리드: 셀트리온
상세 →NCT04512872
1상완료· SARS-CoV-2 Infection
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
리드: 셀트리온
상세 →NCT04593641
1상완료· Healthy Subjects
Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects
리드: 셀트리온
상세 →NCT04428814
1상완료· SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
리드: 셀트리온
상세 →NCT04525079
1상완료· Healthy
To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
리드: 셀트리온
상세 →NCT04018313
1상완료· Healthy
To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17
리드: 셀트리온
상세 →NCT04295356
1상완료· Healthy
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
리드: 셀트리온
상세 →NCT03970824
1상완료· Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants
리드: 셀트리온
상세 →NCT03918967
1상완료· Health, Subjective
CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects
리드: 셀트리온
상세 →NCT03446976
1상완료· Healthy
To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin
리드: 셀트리온
상세 →NCT03247673
1상완료· Crohn's Disease
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
리드: 셀트리온
상세 →NCT02883452
1상완료· Healthy Volunteers
Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin
리드: 셀트리온
상세 →NCT02665637
1상완료· Rheumatoid Arthritis
Long-Term Efficacy and Safety of CT-P10 in Patients With RA
리드: 셀트리온
상세 →NCT01873443
1상완료· Ankylosing Spondylitis
An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1
리드: 셀트리온
상세 →NCT01571206
1상완료· Rheumatoid Arthritis
Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis
리드: 셀트리온
상세 →NCT01534884
1상조기 종료· Diffuse Large B-Cell Lymphoma
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial
리드: 셀트리온
상세 →NCT01534949
1상완료· Ankylosing Spondylitis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
리드: 셀트리온
상세 →NCT01220518

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.